-
Something wrong with this record ?
Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial
Rubén Reyes-Sosa, Agustin Lugo-Radillo, Lizzet Cruz-Santiago, Celia Rubí García-Cruz, Oliver Mendoza-Cano
Language English Country Czech Republic
Document type Evaluation Study
- MeSH
- Anti-Inflammatory Agents, Non-Steroidal MeSH
- Injections, Intra-Articular MeSH
- Humans MeSH
- Osteoarthritis drug therapy therapy MeSH
- Platelet-Rich Plasma MeSH
- Rheumatic Diseases MeSH
- Blood Platelets MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Evaluation Study MeSH
Background: Oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics and intra-articular corticosteroid injections are the recommended first line of treatment for knee osteoarthritis (OA); however, they have serious side effects. Platelet-rich plasma (PRP) has been posited as an effective and safer alternative treatment for knee OA. Hitherto, there is only one study comparing the effectiveness of PRP against an NSAID. Aim of the study: The aim of this study was to determine the effectiveness of PRP against celecoxib in the treatment of early knee OA. Methods: 60 patients with knee OA grade II and III were randomly alocated in two groups. Group 1 received one injection of autologous PRP in each affected knee, with a reinjection after 15 days; Group 2 received 200 mg of oral celecoxib each 24 h for a year. Visual Analogue Scale (VAS), total Western Ontario and McMaster Universities Arthritis Index (WOMAC) and WOMAC subscales for pain, stiffness and function were measured at baseline and at 1, 3, 6 and 12 months after the start of the treatment. Results: At the end of the study PRP was significantly better than celecoxib (p < 0.05) in improving VAS (40.40%), total WOMAC (58.95%) and WOMAC subscales of pain (50.60%), stiffness (34.13%) and function (51.90%). Significant differences remained after adjusting for age, sex or knee OA grade II or III. Conclusions: Intra-articular PRP is significantly better than celecoxib in improving pain, function and stiffness in early knee OA. This significant difference is independent of age, sex or knee OA grade II or III.
CONACYT Universidad Autónoma Benito Juárez de Oaxaca Faculty of Medicine and Surgery Oaxaca Mexico
Instituto Mexicano del Seguro Social Hospital General de Zona No 1 Oaxaca Mexico
Universidad de Colima Faculty of Civil Engineering Colima Mexico
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20017238
- 003
- CZ-PrNML
- 005
- 20210427103634.0
- 007
- ta
- 008
- 201102s2020 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2020.012 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Reyes-Sosa, Rubén $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
- 245 10
- $a Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial / $c Rubén Reyes-Sosa, Agustin Lugo-Radillo, Lizzet Cruz-Santiago, Celia Rubí García-Cruz, Oliver Mendoza-Cano
- 504 __
- $a Literatura
- 520 9_
- $a Background: Oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics and intra-articular corticosteroid injections are the recommended first line of treatment for knee osteoarthritis (OA); however, they have serious side effects. Platelet-rich plasma (PRP) has been posited as an effective and safer alternative treatment for knee OA. Hitherto, there is only one study comparing the effectiveness of PRP against an NSAID. Aim of the study: The aim of this study was to determine the effectiveness of PRP against celecoxib in the treatment of early knee OA. Methods: 60 patients with knee OA grade II and III were randomly alocated in two groups. Group 1 received one injection of autologous PRP in each affected knee, with a reinjection after 15 days; Group 2 received 200 mg of oral celecoxib each 24 h for a year. Visual Analogue Scale (VAS), total Western Ontario and McMaster Universities Arthritis Index (WOMAC) and WOMAC subscales for pain, stiffness and function were measured at baseline and at 1, 3, 6 and 12 months after the start of the treatment. Results: At the end of the study PRP was significantly better than celecoxib (p < 0.05) in improving VAS (40.40%), total WOMAC (58.95%) and WOMAC subscales of pain (50.60%), stiffness (34.13%) and function (51.90%). Significant differences remained after adjusting for age, sex or knee OA grade II or III. Conclusions: Intra-articular PRP is significantly better than celecoxib in improving pain, function and stiffness in early knee OA. This significant difference is independent of age, sex or knee OA grade II or III.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a osteoartróza $x farmakoterapie $x terapie $7 D010003
- 650 _2
- $a trombocyty $7 D001792
- 650 _2
- $a plazma bohatá na destičky $7 D053657
- 650 _2
- $a injekce intraartikulární $7 D007270
- 650 _2
- $a antiflogistika nesteroidní $7 D000894
- 650 _2
- $a revmatické nemoci $7 D012216
- 655 _2
- $a hodnotící studie $7 D023362
- 700 1_
- $a Lugo-Radillo, Agustin $u CONACYT - Universidad Autónoma Benito Juárez de Oaxaca, Faculty of Medicine and Surgery, Oaxaca, Mexico
- 700 1_
- $a Ruiz-Olivera, Maria del Rocio $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
- 700 1_
- $a Cruz-Santiago, Lizzet $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
- 700 1_
- $a García-Cruz, Celia Rubí $u Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1, Oaxaca, Mexico
- 700 1_
- $a Mendoza-Cano, Oliver $u Universidad de Colima, Faculty of Civil Engineering, Colima, Mexico
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 18, č. 2-3 (2020), s. 41-45 $w MED00012667
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2020/02/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y p $z 0
- 990 __
- $a 20201102142735 $b ABA008
- 991 __
- $a 20210415103624 $b ABA008
- 999 __
- $a ok $b bmc $g 1578635 $s 1107424
- BAS __
- $a 3
- BMC __
- $a 2020 $b 18 $c 2-3 $d 41-45 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $c NLK197 $d 20210415 $a NLK 2020-40/dk